New Cosponsor — Apr 19, 2012
New Cosponsor: Sen. Mark Begich [D-AK, 2009-2014]
The bill now has 7 cosponsors (7 Democrats).
Apr 18, 2012
112th Congress, 2011–2013
This bill was introduced on April 18, 2012, in a previous session of Congress, but was not enacted.
Senior Senator from Vermont
Read Text »
Last Updated: Apr 18, 2012
Length: 2 pages
A bill to permit manufacturers of generic drugs to provide additional warnings with respect to such drugs in the same manner that the Food and Drug Administration allows brand names to do so.
Legislative action may be ocurring on one of these bills in lieu of or in parallel to action on this bill.
Referred to Committee
Last Action: Apr 18, 2012
The “S.” in “S. 2295” means this is a Senate bill in the United States Congress. A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
The bill’s title was written by its sponsor.
The committee chair determines whether a bill will move past the committee stage.
There have been no votes related to this bill.
Search for similar bills.
Click a format for a citation suggestion:
Civic Impulse. (2015). S. 2295 — 112th Congress: Patient Safety and Generic Labeling Improvement Act. Retrieved from https://www.govtrack.us/congress/bills/112/s2295
“S. 2295 — 112th Congress: Patient Safety and Generic Labeling Improvement Act.” www.GovTrack.us. 2012. August 3, 2015 <https://www.govtrack.us/congress/bills/112/s2295>
|title=S. 2295 (112th)
|accessdate=August 3, 2015
|author=112th Congress (2012)
|date=April 18, 2012
|quote=Patient Safety and Generic Labeling Improvement Act